<DOC>
	<DOCNO>NCT00003267</DOCNO>
	<brief_summary>RATIONALE : The use pelvic drain may help prevent complication follow radical hysterectomy pelvic lymphadenectomy . It know whether receive pelvic drain surgery effective receiving pelvic drain surgery patient uterine , cervical , vaginal cancer . PURPOSE : Randomized phase III trial determine use pelvic drain follow radical hysterectomy pelvic lymphadenectomy effective treating patient uterine , cervical , vaginal cancer .</brief_summary>
	<brief_title>Pelvic Drains After Radical Hysterectomy Treating Patients With Uterine , Cervical , Vaginal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate postoperative complication associate use omission pelvic drain follow radical hysterectomy node dissection include suture vaginal cuff peritonealization . OUTLINE : This randomize , two-arm study . All patient receive radical hysterectomy ( Rutledge-Piver II-III type ) pelvic lymphadenectomy , without pelvic parietal peritonealization , suture vaginal cuff closure fascia cutaneous layer ; lumboaortic node dissection optional . Patients randomize surgery one two arm : arm I receive pelvic drain arm II . Those arm I drain applied pelvis , lymph collect vaginal and/or transabdominal drain locate retroperitoneal fossa . Drains removed loss le 50 mL 24 hour . Patients arm follow 2-3 month 12 month surgery . PROJECTED ACCRUAL : 214 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Postoperative Complications</mesh_term>
	<mesh_term>Vaginal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven cervical , vaginal , endometrial carcinoma abdominal radical hysterectomy ( RutledgePiver II III type ) pelvic node dissection indicate The follow exclude : Extensive intraoperative retroperitoneal blood loss ( 3000 mL ) Excessive postsurgical hemorrhage ooze wound area require postoperative drainage Concurrent urinary bowel injury/deviation surgical procedure urinary incontinence ( Burch etc . ) Application prophylactic abdominal mesh subsequent radiotherapy PATIENT CHARACTERISTICS : Age : Not specify Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior neoadjuvant chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage I cervical cancer</keyword>
	<keyword>stage II cervical cancer</keyword>
	<keyword>stage I vaginal cancer</keyword>
	<keyword>stage II vaginal cancer</keyword>
	<keyword>stage I endometrial carcinoma</keyword>
	<keyword>stage II endometrial carcinoma</keyword>
	<keyword>infection</keyword>
	<keyword>perioperative/postoperative complication</keyword>
</DOC>